IMPORTANT SAFETY INFORMATION
Infections: Serious, including fatal, infections occurred in 19% of 317 patients treated with ALIQOPA monotherapy. The most common serious infection was pneumonia. Monitor patients for signs and symptoms of infection and withhold ALIQOPA for Grade 3 and higher infection. Continue reading below
© 2022 Bayer. All rights reserved. Bayer, the Bayer Cross, Aliqopa, and ARC are registered trademarks of Bayer.
This site is intended for US audiences only.
Site last modified: 03/2022
